Pharmacogenomics: Application to the Management of Cardiovascular Disease
- 14 September 2011
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 90 (4) , 519-531
Abstract
The past decade has seen substantial advances in cardiovascular pharmacogenomics. Genetic determinants of response to clopidogrel and warfarin have been defined, resulting in changes to the product labels for these drugs that suggest the use of genetic information as a guide for therapy. Genetic tests are available, as are guidelines for incorporation of genetic information into patient-care decisions. These guidelines and the literature supporting them are reviewed herein. Significant advances have also been made in the pharmacogenomics of statin-induced myopathy and the response to β-blockers in heart failure, although the clinical applications of these findings are less clear. Other areas hold promise, including the pharmacogenomics of antihypertensive drugs, aspirin, and drug-induced long-QT syndrome (diLQTS). The potential value of pharmacogenomics in the discovery and development of new drugs is also described. In summary, pharmacogenomics has current applications in the management of cardiovascular disease, with clinically relevant data continuing to mount.Keywords
This publication has 74 references indexed in Scilit:
- A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failureProceedings of the National Academy of Sciences, 2006
- Long QT syndrome: reduced repolarization reserve and the genetic linkJournal of Internal Medicine, 2005
- CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese populationPharmacogenetics and Genomics, 2005
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damagePharmacogenetics and Genomics, 2005
- β-adrenergic Receptor Polymorphisms and Responses during Titration of Metoprolol Controlled Release/extended Release in Heart Failure*Clinical Pharmacology & Therapeutics, 2005
- CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet™ systematic review and meta-analysisGenetics in Medicine, 2005
- Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1 , and KCNE2 in drug-induced long QT syndrome patientsJournal of Molecular Medicine, 2004
- ACE and α-Adducin Polymorphism as Markers of Individual Response to Diuretic TherapyHypertension, 2003
- Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de PointesCirculation, 2002